Open access
Oct 2026
Perioperative Camrelizumab and Apatinib for High‐Risk Resectable Hepatocellular Carcinoma: A Phase II Study
Perioperative camrelizumab combined with apatinib demonstrated promising efficacy and manageable safety in high‐risk resectable HCC.
Yun-Long Cui, Xu Bao, George W. Yu et al.
· MedComm · 0 citations